AssetMemo

Preview Research free. Sign in to unlock 3 full asset or company pages every day, no card needed.Sign in to unlock this page

Company profile

Biocad

Biotechnology (biosimilars + biologics)

Privately held: no public share price · Russia

Assets

(8 total)
8Total Assets
0Approved
8Phase 3 / Filed
0Phase 1–2 / Early
6Diseases
Quick filter:
Showing 8 of 8 assets
Target & Modality
AcellbiaNo recent activity
Phase 3
CD20Monoclonal antibody
Rheumatoid Arthritis
BCD-132No recent activity
Phase 3
CD20Monoclonal antibody
Multiple Sclerosis
BCD-248
Phase 3
BCMA x CD3Multispecific antibody
Multiple Myeloma
BCD-264
Phase 3
CD38Monoclonal antibody
Multiple Myeloma
BCD-281
Phase 3
CD20Monoclonal antibody
Multiple Sclerosis
Divozilimab
Phase 3
CD20Monoclonal antibody
Systemic Lupus ErythematosusMultiple Sclerosis
Levilimab
Phase 3
IL-6 receptorMonoclonal antibody
Rheumatoid Arthritis
netakimab
Phase 3
IL-17Monoclonal antibody
Psoriatic ArthritisPsoriasis

Upcoming events

Unlock with Research ↗
Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Unlock with Research ↗
Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share prices are end-of-day closes, delayed by 24 hours.